Changes in Interleukin-35 (IL-35), Anti-TSHR antibody and Human Insulin- like Growth Factor 1 Receptor (IGF1R) in Graves’ Disease Patients Treatedwith Radioactive Iodine - Egyptian Knowledge Bank - troweb

293431

Changes in Interleukin-35 (IL-35), Anti-TSHR antibody and Human Insulin- like Growth Factor 1 Receptor (IGF1R) in Graves’ Disease Patients Treatedwith Radioactive Iodine

Article

Last updated: 03 Jan 2025

Overview Similar Items

Article

Effect of Radioactive Iodine Therapy on Interleukin-2 (IL-2), IL-17 and Physiological Parameters in Iraqi Patients with Graves’ Disease

Article

The Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease

Article

The Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves' Disease

Article

From Hyperthyroidism to Hypothyroidism: A Detailed Analysis of Radioactive Iodine Therapy Outcomes Based on Dosage

Article

Study of Selenium Status in Grave’s Disease Patients

Article

A Comparative Study between Different Therapeutic Modalities for the Management of Patients with Graves' Disease

Article

Impact of lymphocytic thyroiditis on the outcome of papillary thyroid carcinoma treated with radioactive iodine I-131

Article

Effect of Different Ablative Doses of Radioactive Iodine in Patients with Differentiated Thyroid Carcinoma and Cervical Lymph Node Metastasis

Article

The Impact of Thyroid Stunning on Radioactive Iodine Ablation Compared to Other Risk Factors

Article

14 years Radioiodine therapy in management of thyrotoxicosis (single institutional study)